Rifampicin is a key antibiotic for treating tuberculosis, but resistance to it is rising. Researchers tested rifampicin together with a probe compound called AAP-SO2 to try a different approach. Lab work showed AAP-SO2 binds bacterial RNA polymerase at a different site and slows the elongation step of transcription.
Because the two drugs block different steps, the team calls the idea vertical inhibition. AAP-SO2 killed bacteria with the common βS450L resistance mutation in culture and made those bacteria vulnerable to rifampicin again. In liquid culture the drugs had additive effects, but in a rabbit model they worked together much more strongly. The researchers will develop a more stable drug from the probe and have filed a provisional patent on the dual-inhibition idea.
Difficult words
- rifampicin — antibiotic used to treat tuberculosis
- resistance — ability of bacteria to survive a drug
- probe — small test compound used in experiments
- transcription — process of making RNA from DNA
- elongation — step when new RNA strand grows
- inhibition — action of stopping or slowing a process
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is it important to find ways to treat bacteria that are resistant to antibiotics?
- What question would you ask the researchers about testing the drugs in rabbits?
- Do you think using two drugs that block different steps is a good idea? Why or why not?
Related articles
AI and Wearable Devices for Type 2 Diabetes
A meta-review from the University at Buffalo examines AI-enhanced wearable devices for Type 2 diabetes and prediabetes. The study finds predictive benefits and important limits, and calls for larger, more transparent studies before routine clinical use.
People with disabilities in Kenya and Nigeria faced hardship during COVID-19
During the COVID-19 pandemic, people with disabilities in poor urban areas of Kenya and Nigeria had worse access to health care, lost income and faced higher costs. Researchers and advocates call for closer, accessible services and fair relief.
